GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Receivables Turnover

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Receivables Turnover : 2.53 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hunan Er-Kang Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was ¥276 Mil. Hunan Er-Kang Pharmaceutical Co's average Accounts Receivable for the three months ended in Mar. 2024 was ¥109 Mil. Hence, Hunan Er-Kang Pharmaceutical Co's Receivables Turnover for the three months ended in Mar. 2024 was 2.53.


Hunan Er-Kang Pharmaceutical Co Receivables Turnover Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Receivables Turnover Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.79 6.68 8.27 11.68 14.69

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 3.79 3.19 2.98 2.53

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's Receivables Turnover falls into.



Hunan Er-Kang Pharmaceutical Co Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Hunan Er-Kang Pharmaceutical Co's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Receivables Turnover (A: Dec. 2023 )
=Revenue / Average Total Inventories
=Revenue (A: Dec. 2023 ) / ((Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count )
=1783.119 / ((133.693 + 109.154) / 2 )
=1783.119 / 121.4235
=14.69

Hunan Er-Kang Pharmaceutical Co's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

Receivables Turnover (Q: Mar. 2024 )
=Revenue / Average Total Inventories
=Revenue (Q: Mar. 2024 ) / ((Accounts Receivable (Q: Dec. 2023 ) + Accounts Receivable (Q: Mar. 2024 )) / count )
=275.789 / ((109.154 + 108.797) / 2 )
=275.789 / 108.9755
=2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Hunan Er-Kang Pharmaceutical Co Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines